Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) insider Natarajan Sethuraman sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $15,000.00. Following the completion of the transaction, the insider now owns 208,032 shares […]
Contrasting Oncotelic Therapeutics (OTCMKTS:OTLC) and Entrada Therapeutics (NASDAQ:TRDA) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
BOSTON, May 16, 2024 Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage.